Medicus Pharma (NASDAQ: MDCX) has entered into a $22 million structured financing agreement with an institutional investor, providing the biotech with non-dilutive capital to advance its clinical pipeline.

The facility comprises two secured promissory notes: $12.86 million at 8.75% interest with a 6.5% original issue discount, available immediately, and a further $10 million at 5% interest held in a collateralised deposit account to be released upon achievement of specified milestones. Combined with existing cash, the financing is expected to bring Medicus's pro forma cash position to approximately $30 million, providing a projected operating runway of more than 24 months.

Proceeds will fund clinical development programmes, strategic business development, and general working capital, including repayment of roughly $2.5 million in outstanding debt. CEO Dr. Raza Bokhari described the structure as providing "meaningful capital flexibility" while preserving the company's ability to pursue expanding strategic initiatives. Maxim Group acted as exclusive placement agent.

Within a single business week in May 2026, the three most senior positions governing US drug and biologics review turned over simultaneously. Commissioner Marty Makary resigned on 12 May, acting CDER director Tracy Beth Høeg was fired on 15 May, and CBER's Katherine Szarama was replaced by Karim Mikhail, leaving Acting Commissioner Kyle Diamantas, whose background is in food regulation, overseeing both centres without a publicly named CDER successor.

The operational risk for sponsors is specific: centre-director signatures are required for major dispute resolutions, clinical holds, and accelerated approval proceedings. With no documented delegation chain published in the Federal Register, pre-submission meeting commitments made under prior leadership face potential interpretive ambiguity.

Sponsors with NDAs or BLAs under review should formally document assigned division directors, reconfirm written meeting agreements, and monitor whether FDA publishes a formal 21 CFR § 5.10 delegation notice, its absence would extend uncertainty into a summer cycle carrying several high-profile PDUFA dates.

For 20 years, Prix Galien USA has honored the breakthroughs shaping the future of healthcare and improving lives worldwide. Often regarded by the industry as the equivalent of the Nobel Prize of biopharmaceutical research, this is where innovation meets impact.

From groundbreaking therapies to life-saving technologies, this is more than an event, it’s a global movement advancing human health.

Follow The Galien Foundation on LinkedIn to stay updated on announcements, speakers, and innovations leading up to the event.

Biogen has closed its acquisition of Apellis Pharmaceuticals for approximately $5.6 billion in upfront consideration, plus contingent value rights of up to $4 per share tied to future SYFOVRE sales milestones. The deal makes Apellis a wholly owned subsidiary and brings pegcetacoplan, the first-ever FDA-approved treatment for geographic atrophy secondary to AMD, into Biogen's expanding complement-focused portfolio.

For retina specialists, near-term prescribing protocols are unchanged, though a prefilled syringe formulation is expected to reach FDA submission shortly, and biomarker-driven patient selection strategies remain under investigation.

The acquisition carries strategic logic beyond ophthalmology: Apellis' nephrology infrastructure, built around EMPAVELI's kidney indications, is expected to support Biogen's commercial readiness for felzartamab, its anti-CD38 antibody in Phase III for antibody-mediated kidney rejection. The deal consolidates retinal and renal complement biology under a single commercial umbrella for the first time.

For the first time in ASCO's history, one of the conference's coveted headline presentation slots has been awarded to a clinical trial conducted exclusively in China, a milestone that crystallises the dramatic transformation of China's pharmaceutical sector from a peripheral player into a formidable competitor in drug innovation.

The featured drug, ivonescimab, combines immune checkpoint inhibition with tumour angiogenesis blockade. Its US rights were acquired by Summit Therapeutics, which is separately running global trials for FDA approval, though early results from the US cohort failed to meet a key statistical threshold, raising questions about cross-population efficacy.

The broader trend is striking: roughly half of major pharma licensing deals in 2026 have involved Chinese-origin drugs, up from almost nothing in the 2010s. While some argue competition drives better medicines, critics, including former FDA officials, warn that growing dependence on Chinese innovation poses strategic and clinical risks for American patients.

In an age that looks ahead toward AI-driven drug development, we should also look back at the scientific frameworks set decades ago regarding preclinical research. In every major drug programme, between the first idea and the first human dose, there lies an uncomfortable reality: animals are still used, sometimes usefully, sometimes imperfectly, and increasingly alongside better, human-relevant alternatives.

The John Hopkins Center for Alternatives to Animal Testing (1), established in 1981, shows that this controversial topic has been recognised for decades, with serious efforts made to replace and reduce animal use rather than justify its use indefinitely.

However, for complete, whole-organism questions, nothing yet fully substitutes a living system with circulating blood, an immune response, and multi-organ interactions. That is why regulators still expect animal data before first-in-human studies, and why millions of animals continue to be used each year. Ignoring this fact does not make progress towards animal-free research any closer.

At the same time, clinging to animals as the “gold standard” is scientifically and ethically questionable. New methodologies, such as organ-on-a-chip, advanced 3D cultures, and computational or AI models, can sometimes predict human responses better than the traditional preclinical models. A human Liver-Chip correctly identified 87% of drugs known to cause drug-induced liver injury, whereas all 27 drugs had previously passed preclinical animal testing (2).

Published in 1959, the 3Rs framework (replacement, reduction, refinement) is not just an ethical slogan, it is a scientific strategy for more precise, human-relevant data (3). Now, with the rise of non‑animal preclinical models, we can propose the 3Is for embedding human‑centred methodologies directly into the core of preclinical science: invest, improve, and integrate.

References

1. Goldberg AM. A History of the Johns Hopkins Center for Alternatives to Animal Testing (CAAT): The First 28 Years (1981–2009). Appl Vitro Toxicol. 2015 Jun 1;1(2):99–108. doi:10.1089/aivt.2015.0015

2. Ewart L, Apostolou A, Briggs SA, Carman CV, Chaff JT, Heng AR, et al. Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology. Commun Med. 2022 Dec 6;2(1):154. doi:10.1038/s43856-022-00209-1

3.Hubrecht RC, Carter E. The 3Rs and Humane Experimental Technique: Implementing Change. Anim Open Access J MDPI. 2019 Sep 30;9(10):754. doi:10.3390/ani9100754 PubMed PMID: 31575048; PubMed Central PMCID: PMC6826930.